These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 24953743)

  • 1. Quality of life in Parkinson's disease patients with motor fluctuations and dyskinesias in five European countries.
    Hechtner MC; Vogt T; Zöllner Y; Schröder S; Sauer JB; Binder H; Singer S; Mikolajczyk R
    Parkinsonism Relat Disord; 2014 Sep; 20(9):969-74. PubMed ID: 24953743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of dyskinesias in Parkinson's disease on quality of life and health-related costs: a prospective European study.
    Péchevis M; Clarke CE; Vieregge P; Khoshnood B; Deschaseaux-Voinet C; Berdeaux G; Ziegler M;
    Eur J Neurol; 2005 Dec; 12(12):956-63. PubMed ID: 16324089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quality of life in early Parkinson's disease: impact of dyskinesias and motor fluctuations.
    Marras C; Lang A; Krahn M; Tomlinson G; Naglie G;
    Mov Disord; 2004 Jan; 19(1):22-8. PubMed ID: 14743356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of the motor complications of Parkinson's disease on the quality of life.
    Chapuis S; Ouchchane L; Metz O; Gerbaud L; Durif F
    Mov Disord; 2005 Feb; 20(2):224-30. PubMed ID: 15384126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of combining levodopa with entacapone on quality of life and activities of daily living in patients experiencing wearing-off type fluctuations.
    Reichmann H; Boas J; Macmahon D; Myllyla V; Hakala A; Reinikainen K;
    Acta Neurol Scand; 2005 Jan; 111(1):21-8. PubMed ID: 15595934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose treatment with pergolide in Parkinson's disease patients with motor fluctuations and dyskinesias.
    Storch A; Trenkwalder C; Oehlwein C; Winkelmann J; Polzer U; Hundemer HP; Schwarz J
    Parkinsonism Relat Disord; 2005 Sep; 11(6):393-8. PubMed ID: 15993640
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of non-motor symptoms on health-related and perceived quality of life in Parkinson's disease.
    Santos-García D; de la Fuente-Fernández R
    J Neurol Sci; 2013 Sep; 332(1-2):136-40. PubMed ID: 23890935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neurostimulation for Parkinson's disease with early motor complications.
    Schuepbach WM; Rau J; Knudsen K; Volkmann J; Krack P; Timmermann L; Hälbig TD; Hesekamp H; Navarro SM; Meier N; Falk D; Mehdorn M; Paschen S; Maarouf M; Barbe MT; Fink GR; Kupsch A; Gruber D; Schneider GH; Seigneuret E; Kistner A; Chaynes P; Ory-Magne F; Brefel Courbon C; Vesper J; Schnitzler A; Wojtecki L; Houeto JL; Bataille B; Maltête D; Damier P; Raoul S; Sixel-Doering F; Hellwig D; Gharabaghi A; Krüger R; Pinsker MO; Amtage F; Régis JM; Witjas T; Thobois S; Mertens P; Kloss M; Hartmann A; Oertel WH; Post B; Speelman H; Agid Y; Schade-Brittinger C; Deuschl G;
    N Engl J Med; 2013 Feb; 368(7):610-22. PubMed ID: 23406026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk and course of motor complications in a population-based incident Parkinson's disease cohort.
    Bjornestad A; Forsaa EB; Pedersen KF; Tysnes OB; Larsen JP; Alves G
    Parkinsonism Relat Disord; 2016 Jan; 22():48-53. PubMed ID: 26585090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Levodopa Effect and Motor Function in Late Stage Parkinson's Disease.
    Rosqvist K; Horne M; Hagell P; Iwarsson S; Nilsson MH; Odin P
    J Parkinsons Dis; 2018; 8(1):59-70. PubMed ID: 29480220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease.
    Hauser RA; McDermott MP; Messing S
    Arch Neurol; 2006 Dec; 63(12):1756-60. PubMed ID: 17172616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Globus pallidus stimulation improves both motor and nonmotor aspects of quality of life in advanced Parkinson's disease.
    Rodrigues JP; Walters SE; Watson P; Stell R; Mastaglia FL
    Mov Disord; 2007 Oct; 22(13):1866-70. PubMed ID: 17659634
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk factors in development of motor complications in Chinese patients with idiopathic Parkinson's disease.
    Kum WF; Gao J; Durairajan SS; Man SC; Xie LX; Lu JH; Fong WL; Li M
    J Clin Neurosci; 2009 Aug; 16(8):1034-7. PubMed ID: 19428256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determinants of the quality of life in Parkinson's disease: results of a cohort study from Southwest China.
    Wu Y; Guo XY; Wei QQ; Song W; Chen K; Cao B; Ou RW; Zhao B; Shang HF
    J Neurol Sci; 2014 May; 340(1-2):144-9. PubMed ID: 24679837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. L-DOPA-induced dyskinesias, motor fluctuations and health-related quality of life: the COPARK survey.
    Perez-Lloret S; Negre-Pages L; Damier P; Delval A; Derkinderen P; Destée A; Meissner WG; Tison F; Rascol O;
    Eur J Neurol; 2017 Dec; 24(12):1532-1538. PubMed ID: 28940893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Motor fluctuations and dyskinesias in Parkinson's disease: variables that discriminate both complications in a sample of 285 patients].
    Gómez JC; Rouco I; Velasco F; Tijero B; Garamendi I; Lezcano E; Zarranz JJ
    Neurologia; 2008 Oct; 23(8):494-8. PubMed ID: 18770057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health-related quality of life and healthcare utilisation in patients with Parkinson's disease: impact of motor fluctuations and dyskinesias.
    Dodel RC; Berger K; Oertel WH
    Pharmacoeconomics; 2001; 19(10):1013-38. PubMed ID: 11735671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges.
    Katzenschlager R; Hughes A; Evans A; Manson AJ; Hoffman M; Swinn L; Watt H; Bhatia K; Quinn N; Lees AJ
    Mov Disord; 2005 Feb; 20(2):151-7. PubMed ID: 15390035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The impact of levodopa-carbidopa intestinal gel on health-related quality of life in Parkinson's disease].
    Kovács N; Aschermann Z; Ács P; Bosnyák E; Deli G; Janszky J; Komoly S
    Ideggyogy Sz; 2014 Jul; 67(7-8):245-50. PubMed ID: 25509365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intrajejunal levodopa infusion in Parkinson's disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life.
    Honig H; Antonini A; Martinez-Martin P; Forgacs I; Faye GC; Fox T; Fox K; Mancini F; Canesi M; Odin P; Chaudhuri KR
    Mov Disord; 2009 Jul; 24(10):1468-74. PubMed ID: 19425079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.